Fiera Capital Corp Has $33.15 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Fiera Capital Corp decreased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 4.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 107,422 shares of the biopharmaceutical company's stock after selling 4,458 shares during the period. Fiera Capital Corp owned approximately 0.49% of Madrigal Pharmaceuticals worth $33,147,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its holdings in shares of Madrigal Pharmaceuticals by 47.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 68 shares during the period. Quest Partners LLC lifted its stake in shares of Madrigal Pharmaceuticals by 172.8% during the 3rd quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company's stock worth $123,000 after purchasing an additional 368 shares during the period. KBC Group NV lifted its stake in shares of Madrigal Pharmaceuticals by 73.5% during the 4th quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company's stock worth $188,000 after purchasing an additional 258 shares during the period. Truist Financial Corp purchased a new position in shares of Madrigal Pharmaceuticals in the 2nd quarter worth $216,000. Finally, Miracle Mile Advisors LLC purchased a new position in shares of Madrigal Pharmaceuticals in the 4th quarter worth $216,000. Institutional investors and hedge funds own 98.50% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on MDGL shares. Cantor Fitzgerald reiterated a "neutral" rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 20th. UBS Group raised their target price on shares of Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a "buy" rating in a report on Friday, November 1st. B. Riley lifted their price target on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. JMP Securities reaffirmed a "market outperform" rating and set a $427.00 price target on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. Finally, HC Wainwright raised their price objective on shares of Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the company a "buy" rating in a research note on Tuesday, January 14th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $351.67.

Madrigal Pharmaceuticals Trading Down 4.1 %

NASDAQ MDGL traded down $14.51 on Monday, hitting $337.20. 372,386 shares of the stock were exchanged, compared to its average volume of 484,737. Madrigal Pharmaceuticals, Inc. has a 52-week low of $189.00 and a 52-week high of $368.29. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The company has a market capitalization of $7.35 billion, a price-to-earnings ratio of -13.44 and a beta of -0.38. The company's 50-day moving average price is $316.98 and its two-hundred day moving average price is $279.75.

Insiders Place Their Bets

In related news, CEO William John Sibold sold 1,584 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $335.24, for a total value of $531,020.16. Following the completion of the sale, the chief executive officer now owns 54,303 shares of the company's stock, valued at approximately $18,204,537.72. The trade was a 2.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert E. Waltermire sold 442 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, January 17th. The shares were sold at an average price of $273.41, for a total transaction of $120,847.22. Following the completion of the sale, the vice president now directly owns 5,058 shares of the company's stock, valued at approximately $1,382,907.78. The trade was a 8.04 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,090 shares of company stock worth $3,883,621. Corporate insiders own 22.80% of the company's stock.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.